Option Chain

Tarsus Pharmaceuticals Inc

TARSNASDAQ · USD

69.23USD-3.41 (-4.70%)

529

Tarsus Pharmaceuticals Inc (TARS) Option Chain

Tarsus Pharmaceuticals Inc trades at $69.23, down 4.70%, with an IV Rank of 87.70%. This is high versus the past year, and the company carries a market cap of $3,581M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $70.00 strike shows calls at $5.20 / $10.00 and puts at $1.55 / $6.40, both carrying about $5.40 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $75.00 calls, at 6 contracts, and the $75.00 puts, at 6, as of Nov 3, 2026.

Tracking the TARS option chain helps you see every strike and expiry on Tarsus Pharmaceuticals Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of TARS options activity at a glance. Use our scanner to monitor the TARS option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For TARS stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where TARS options are being actively traded, and where they are not.

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
26.37	2	0	6.67	4.23	8.50	13.30	65.00	-11.35	—	4.90	0.00	4.90	0	4	73.63
34.06	0	0	7.17	1.73	6.50	11.30	67.50	-7.94	0.50	5.20	0.00	2.85	0	4	65.94
42.16	0	0	7.60	0.00	5.20	10.00	70.00	-4.53	1.55	6.40	0.77	3.21	0	37	57.84
50.32	2	0	6.15	0.00	4.30	8.00	72.50	-1.12	3.00	6.70	3.27	1.58	0	4	49.68
58.19	66	6	5.25	0.00	3.30	7.20	75.00	+2.29	4.40	8.00	5.77	0.43	6	7	41.81

As of Nov 3, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank87.70% High
Market cap (M$)3,581
52 weeks high-20.64%
52 weeks low34.79%
Analyst recommendationStrong Buy
1.09
Target price$98.89
42.84% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-03
P/E—
Future P/E71.45
EPS (ttm)-1.08
EPS growth next 5 years—

As of Nov 3, 2026

Browse all Option Chain tickers